BMS Reports the US FDA’s Acceptance of BLA for Opdivo to Treat Clear Cell Renal Cell Carcinoma
Shots:
- The US FDA has accepted the BLA of SC Opdivo co-formulated with Halozyme’s recombinant human hyaluronidase (rHuPH20) for all the approved solid tumor indications as monotx. and in combinations with the decision anticipated on Feb 28, 2025
- The BLA was based on the P-III (CheckMate -67T) trial assessing Opdivo (SC) co-formulated with rHuPH20 vs Opdivo (IV) for treating advanced or metastatic clear cell renal cell carcinoma (ccRCC) patients previously treated with systemic therapy
- The study demonstrated noninferiority of Cavgd28 & Cminss along with ORR using Opdivo (SC) vs Opdivo (IV). The safety profile of SC formulation was comparable with the IV formulation; data was highlighted at ASCO GU 2024
Ref: BMS | Image: BMS
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
